

05.05.2021

16:00 - 17:00	Type: Industry Satellite Symposia Title: Industry Satellite symposium 1	Channel 1
16:00 - 17:00	Type: Industry Satellite Symposia Title: Industry Satellite symposium 2	Channel 2
17:30 - 18:30	Type: Industry Satellite Symposia Title: Industry Satellite symposium 3	Channel 1
17:30 - 18:30	Type: Industry Satellite Symposia Title: Industry Satellite symposium 4	Channel 2
19:00 - 20:00	Type: Industry Satellite Symposia Title: Industry Satellite symposium 5	Channel 1
19:00 - 20:00	Type: Industry Satellite Symposia Title: Industry Satellite symposium 6	Channel 2

06.05.2021

16:00 - 17:00	Type: Industry Satellite Symposia Title: Industry Satellite symposium 7	Channel 1
16:00 - 17:00	Type: Industry Satellite Symposia Title: Industry Satellite symposium 8	Channel 2
17:30 - 18:30	Type: Industry Satellite Symposia Title: Industry Satellite symposium 9	Channel 1
17:30 - 18:30	Type: Industry Satellite Symposia Title: Industry Satellite symposium 10	Channel 2
19:00 - 20:00	Type: Industry Satellite Symposia Title: Industry Satellite symposium 11	Channel 1
19:00 - 20:00	Type: Industry Satellite Symposia Title: Industry Satellite symposium 12	Channel 2

07.05.2021

09:00 - 20:00	Type: Poster session Title: e-Poster Display Session	On-Demand e-Poster Display
11:55 - 12:00	Type: Opening Title: Welcome to the ESMO Breast Cancer Virtual Meeting 2021	Channel 1
12:00 - 12:30	Type: Keynote Title: Keynote 1	Channel 1

12:00 - 12:05 **Introduction by the Chair**

12:05 - 12:30 **Title to be defined**

12:45 - 14:00	Type: Educational session Title: Optimal sequence in metastatic HER2+ breast cancer Chair(s): Lisa Carey, US	Channel 1
----------------------	--	------------------

12:45 - 13:00 **Decision-making in metastatic HER2+ BC in 2021**
L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US

13:00 - 13:15 **HER2+ breast cancer: Clinical consequences of biologic heterogeneity**
A. Prat, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

13:15 - 13:30 **Making a chronic disease of metastatic HER2+ breast cancer: Are any cured?**
E. Winer, Harvard Medical School, Boston, US

13:30 - 13:45 **Do CNS metastases in HER2+ BC require a different systemic approach?**
T. Bachelot, Centre Léon Bérard, Lyon, FR

13:45 - 13:55 **Live Q&A**

12:45 - 14:00	Type: Educational session Title: Precision medicine in breast cancer Chair(s): Monica Arnedos, FR	Channel 3
12:45 - 13:00	cfDNA testing for early detection of breast cancer and breast cancer relapse. Ready for prime time? <u>N. Turner</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
13:00 - 13:15	Genomic profiling for mBC patients: Which techniques? To whom, when and how often? <u>M. Arnedos</u> , Institut Gustave Roussy, Villejuif, FR	
13:15 - 13:30	Is there a role for molecular profiling in early breast cancer? <u>C. Sotiriou</u> , Institute Jules Bordet, Brussels, BE	
13:30 - 13:45	Epigenetics in breast cancer: The comeback of an old friend? <u>L. Magnani</u> , Imperial College London-South Kensington Campus, London, GB	
13:45 - 13:55	Live Q&A	
14:15 - 15:30	Type: Educational session Title: Neoadjuvant/ adjuvant treatment in triple negative breast cancer Chair(s): Javier Cortés, ES	Channel 1
14:15 - 14:20	Live introduction	
14:20 - 14:35	The role of the immune environment in TNBC <u>R. Salgado</u> , St-Augustinus Ziekenhuis, Wilrijk, BE	
14:35 - 14:50	How to treat patients with early TNBC on Monday morning <u>R. Dent</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
14:50 - 15:05	The role of immunotherapy in early TNBC <u>P. Schmid</u> , Barts Cancer Institute-Queen Mary University of London, London, GB	
15:05 - 15:20	Potential new drugs with activity in metastatic TNBC <u>J. Cortés</u> , Vall d'Hebron University Hospital, Barcelona, ES	
15:20 - 15:30	Live Q&A	

15:45 - 17:00	Type: Multidisciplinary tumour board Title: Neoadjuvant/ adjuvant treatment of HER2+ Chair(s): David Cameron, GB	Channel 1
15:45 - 15:50	Live introduction	
15:50 - 16:05	Evaluation of HER2 status: What else needs to be known <u>A. Vincent-Salomon</u> , Institut Curie, Paris, FR	
16:05 - 16:20	Can we cure oligometastatic HER2+ disease? <u>D. Cameron</u> , Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB	
16:20 - 16:35	Should we maximise HER2 blockade for triple positive disease? <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	
16:35 - 16:50	Surgery in the time of pathological complete responses: How to adapt to better systemic therapy? <u>H.-B. Lee</u> , Seoul National University Hospital, Seoul, KR	
16:50 - 17:00	Live Q&A	

15:45 - 17:00	Type: Educational session Title: Impact of ethnicity-based differences in breast cancer Chair(s): Seock-Ah Im, KR	Channel 2
15:45 - 15:50	Live introduction	
15:50 - 16:05	Ethnicity, clinico-pathologic difference and outcome of young breast cancer patients <u>E. Copson</u> , Southampton General Hospital Southampton University Hospitals NHS Trust, Southampton, GB	
16:05 - 16:20	Impact of ethnicity on efficacy and toxicity of cyclin d kinase 4/6 inhibitors with endocrine therapy <u>S.-A. Im</u> , SNUH-Seoul National University Hospital, Seoul, KR	
16:20 - 16:35	Pharmacokinetic differences and ethnic variability in tolerance of cytotoxic drugs <u>R. Danesi</u> , University of Pisa - DAM, Pisa, IT	
16:35 - 16:50	Ethnic differences in hereditary breast cancer focusing on BRCAmt in PARPi era <u>Y.H. Park</u> , Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR	
16:50 - 17:00	Live Q&A	

15:45 - 17:00	Type: Educational session Title: Optimal sequence in metastatic ER+ breast cancer Chair(s): Nadia Harbeck, DE	Channel 3
15:45 - 15:50	Live introduction	
15:50 - 16:05	Use of biomarkers to guide treatment selection <u>M. Liu</u> , Mayo Clinic, Rochester, US	
16:05 - 16:20	CDK 4/6i: The established first-line standard? <u>N. Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, DE	
16:20 - 16:35	Progression after CDK 4/6i: How to sequence approved options <u>F. Cardoso</u> , Champalimaud Foundation Cancer Center, Lisbon, PT	
16:35 - 16:50	Progression after CDK 4/6i: New kids on the block <u>P. Aftimos</u> , Institute Jules Bordet, Brussels, BE	
16:50 - 17:00	Live Q&A	

08.05.2021

09:00 - 20:00 **Type: Poster session** **On-Demand e-Poster Display**
Title: e-Poster Display Session

12:00 - 12:30 **Type: Keynote** **Channel 1**
Title: Keynote 2

12:00 - 12:05 **Introduction by the Chair**

12:05 - 12:30 **Title to be defined**

12:45 - 14:00 **Type: Educational session** **Channel 1**
Title: Immunotherapy in metastatic breast cancer
Chair(s): Marleen Kok, NL

12:45 - 12:50 **Live introduction**

12:50 - 13:10 **First-line chemo-IO for mTNBC**
G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

13:10 - 13:30 **Future of PD-1 blockade for ER+ and HER2+ mBC**
S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

13:30 - 13:50 **Potential of IO-IO combinations for mBC**
M. Kok, Netherlands Cancer Institute, Amsterdam, NL

13:50 - 14:00 **Live Q&A**

14:15 - 14:45 **Type: Keynote** **Channel 1**
Title: Keynote 3

14:15 - 14:35 **Introduction by the Chair**

14:35 - 14:55 **Title to be defined**

15:00 - 16:15	<p>Type: Educational session Title: Optimizing the management of premenopausal women with early breast cancer Chair(s): Lucia Del Mastro, IT</p>	Channel 1
15:00 - 15:05	Live introduction	
15:05 - 15:20	<p>Optimal adjuvant/neoadjuvant chemotherapy in triple negative subtype with or without gBRCA mutation S.-B. Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR</p>	
15:20 - 15:35	<p>Adjuvant chemotherapy in hormone-receptor positive tumours: Who to treat and which regimen? S. Delaloge, Institut Gustave Roussy, Villejuif, FR</p>	
15:35 - 15:50	<p>Type and duration of endocrine therapy in hormone receptor positive tumours O. Pagani, HRC - Hopital Riviera-Chablais - Site de Rennaz, Rennaz, CH</p>	
15:50 - 16:05	<p>Preserving fertility in young patients L. Del Mastro, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT</p>	
16:05 - 16:15	Live Q&A	

15:00 - 16:15	Type: Educational session Title: Brain mets management in HER2+ and triple negative breast cancer Chair(s): Yen-Shen Lu, TW	Channel 2
15:00 - 15:05	Live introduction	
15:05 - 15:20	Multidisciplinary management of breast cancer brain metastases	
15:20 - 15:35	HER2 targeting agents for treatment of HER2+ breast cancer with brain mets <u>V. Mueller</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	
15:35 - 15:50	Anti-angiogenesis therapy for breast cancer with brain or leptomeningeal mets <u>Y.-S. Lu</u> , NTUH - National Taiwan University Hospital, Taipei City, TW	
15:50 - 16:05	Emerging treatments for breast cancer with brain metastases <u>A. Awada</u> , Institute Jules Bordet, Brussels, BE	
16:05 - 16:15	Live Q&A	

15:00 - 16:15	Type: Educational session Title: Testing recommendation in breast cancer Chair(s): Frederique Penault-Llorca, FR	Channel 3
15:00 - 15:05	Live introduction	
15:05 - 15:20	State of art for luminal eBC: Ki67 and/or prognostic gene expression signatures? <u>G. Viale</u> , Istituto Europeo di Oncologia, Milan, IT	
15:20 - 15:35	Immunohistochemistry: The new IHC “low” categories (ER, HER2....) and androgen receptor testing <u>C. Denkert</u> , Uniklinikum Giessen und Marburg, Marburg, DE	
15:35 - 15:50	Biomarkers for immunotherapy (PD-L1, TILs, IA...): How and when? <u>F. Penault-Llorca</u> , Jean Perrin Center, Clermont-Ferrand, FR	
15:50 - 16:05	Molecular testing algorithms for metastatic BC <u>F. Rojo</u> , University Hospital Fundacion Jimenez Diaz, Madrid, ES	
16:05 - 16:15	Live Q&A	

16:30 - 17:45 **Type: Educational session** **Channel 1**
Title: Adjuvant treatment early HER+ in breast cancer
Chair(s): Sara Tolaney, US

16:30 - 16:35 **Live introduction**

16:35 - 16:50 **Current standard approaches for early stage HER2+ disease**
V. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

16:50 - 17:05 **How low should we go? Treatment for stage I HER2+ disease**
S. Tolaney, Dana Farber Cancer Institute, Boston, US

17:05 - 17:20 **Can imaging help tailor preoperative HER2-directed therapy?**
E.G.E. De Vries, UMCG - University Medical Center Groningen, Groningen, NL

17:20 - 17:35 **The path ahead: De-escalating and escalating care for early stage HER2+ disease**
S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

17:35 - 17:45 **Live Q&A**

16:30 - 17:45 **Type: Educational session** **Channel 3**
Title: Early drug development in breast cancer
Chair(s): Ana Mafalda Antunes De Melo e Oliveira, ES

16:30 - 16:35 **Live introduction**

16:35 - 16:50 **Epigenetic modulating drugs: Are we hitting the target?**
S. Minucci, European Institute of Oncology, Milan, IT

16:50 - 17:05 **Immunotherapy combos in TNBC**
A.M. Antunes De Melo E Oliveira, Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES

17:05 - 17:20 **Next wave of ADCs: New targets, new drugs, new indications**
V. Boni, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES